Creative Planning’s Nektar Therapeutics NKTR Stock Holding History

Creative Planning’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-67	Closed	-$1K	–	4826
2016 Q4	$1K	Buy	+67	New	+$13.6K	﹤0.01%	4463

Other funds holding NKTR

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Creative Planning's NKTR Position: Q3 2019 in Review

Creative Planning sold out of Nektar Therapeutics (NKTR) in Q3 2019, closing a stake of 619 shares — an estimated $331K sold.

Creative Planning first reported a position in NKTR in Q2 2013 and held it in 23 quarters. The position peaked at $876K in Q4 2014. 287 funds tracked by Wall St. Rank hold NKTR as of Q3 2019.

Creative Planning reported no remaining Nektar Therapeutics position as of Q3 2019 after selling out during the quarter.
Creative Planning sold 619 Nektar Therapeutics shares in Q3 2019, an estimated $331K.
Creative Planning first reported a position in Nektar Therapeutics in Q2 2013 and held it in 23 quarters.
Creative Planning's Nektar Therapeutics position peaked at $876K in Q4 2014.
287 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q3 2019.

Based on Creative Planning's 13F filing for Q3 2019, filed 1 Nov 2019.